23andMe Holding Co. (ME)

NASDAQ: ME · IEX Real-Time Price · USD
2.81
+0.05 (1.81%)
At close: Nov 29, 2022 4:00 PM
2.77
-0.04 (-1.42%)
After-hours: Nov 29, 2022 4:38 PM EST
1.81%
Market Cap 1.26B
Revenue (ttm) 297.62M
Net Income (ttm) -314.54M
Shares Out 449.90M
EPS (ttm) -0.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,578,532
Open 2.83
Previous Close 2.76
Day's Range 2.78 - 2.92
52-Week Range 2.12 - 8.95
Beta 1.24
Analysts Buy
Price Target 5.69 (+102.5%)
Earnings Date Nov 7, 2022

About ME

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeuti... [Read more]

Industry Diagnostics & Research
Founded 2006
Employees 572
Stock Exchange NASDAQ
Ticker Symbol ME
Full Company Profile

Financial Performance

In 2021, ME's revenue was $271.89 million, an increase of 11.47% compared to the previous year's $243.92 million. Losses were -$217.49 million, 18.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ME stock is "Buy." The 12-month stock price forecast is 5.69, which is an increase of 102.49% from the latest price.

Price Target
$5.69
(102.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

23andme founder on the future of health care

This segment originally aired on November 15, 2022. 23andMe Co-Founder and CEO Anne Wojcicki sits down with Yahoo Finance's Anjalee Khemlani at the HLTH conference to discuss the slowdown in growth, con...

1 week ago - Yahoo Finance

23andMe Reports FY2023 Second Quarter Financial Results

Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance

3 weeks ago - GlobeNewsWire

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD2...

The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity The presentation outlines ...

3 weeks ago - GlobeNewsWire

I Bought 2 SPACs That Haven't Lived Up to Expectations -- Here's Why I'm Still Holding Them

These companies haven't performed as well as I thought they would, but I don't plan to sell.

Other symbols: LCID
1 month ago - The Motley Fool

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medi...

FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for confirmatory...

1 month ago - GlobeNewsWire

23andMe to Report FY2023 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, ...

1 month ago - GlobeNewsWire

2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years

They're both using unique and highly efficient approaches to developing and deploying their medicines.

Other symbols: CRSP
1 month ago - The Motley Fool

23andMe to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, ...

1 month ago - GlobeNewsWire

23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1...

Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies Poster to provide details on study design and expansion phase for ong...

1 month ago - GlobeNewsWire

7 Best Reddit Stocks to Buy Now

Reddit's WallStreetBets forum took GameStop stock to unfathomable heights last year, ushering in the meme stock era. Though the retail trading frenzy has dulled considerably, the best Reddit stocks rema...

Other symbols: AAPLAIAMCITTA
1 month ago - InvestorPlace

7 Undervalued Reddit Stocks to Buy Before Wall Street Catches On

Reddit stocks have been so successful (or at least intriguing) that Reddit has quickly become an investing hub. The site has a huge community of investors and traders who use it as a platform for their ...

Other symbols: AAPLHOODITTATLRYWBD
2 months ago - InvestorPlace

Daniel Chu Joins 23andMe as Chief Product Officer

Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries Chu brings over two decades of experience in product managem...

2 months ago - GlobeNewsWire

Ancestry CEO on 23andMe: ‘I think their product is really incredible'

Ancestry CEO Deb Liu joins 'Influencers with Andy Serwer' to discuss the business of DNA and how Ancestry.com competes with other genealogy products.

2 months ago - Yahoo Finance

2 Ex-SPACs I Wouldn't Touch Right Now

I own both of these companies but wouldn't put any more money into them today.

Other symbols: LTCH
2 months ago - The Motley Fool

23andMe Seeks New CFO

Genetics testing provider 23andMe said its chief financial officer will leave the company next month after four years with the company. Steve Schoch notified 23andMe of his resignation earlier this week...

3 months ago - PYMNTS

CFO Transition Rocks 23andMe (ME) Stock

Source: nevodka / Shutterstock.com 23andMe (NASDAQ: ME ) is preparing for a major change at the executive level. Today, the firm announced that CFO Steven Schoch is planning to resign.

3 months ago - InvestorPlace

23andMe stock falls after company says CFO to depart

Shares of 23andMe Holding Co. ME, +1.95% were falling more than 7% in premarket trading Friday after the DNA-testing company disclosed that Chief Financial Officer Stevem Schoch was resigning from the c...

3 months ago - Market Watch

Despite Some Big Losers, These Growth Stocks Are Keeping the Nasdaq Bull Market Going

Investors continue to slowly move away from worries about the economy, inflation, and interest rates, sending growth stocks higher. It's not all good news and positivity, though.

Other symbols: ENVXMQSONOTRUP
3 months ago - The Motley Fool

23andMe will appeal to more and more masses as genetics becomes core part of health care, says CEO

Anne Wojcicki, 23andMe co-founder and CEO, joins 'TechCheck' to discuss the economic impact on 23andMe's business, what the company needs to do to reach the biggest market possible and more.

3 months ago - CNBC Television

23andMe Reports FY2023 First Quarter Financial Results

First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance

3 months ago - GlobeNewsWire

Why 23andMe Stock Jumped Higher on Monday

Trading volume is surging in the hours leading up to its quarterly financial report.

3 months ago - The Motley Fool

23andMe to Report FY2023 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financi...

4 months ago - GlobeNewsWire

23andMe CEO on Telehealth: Sun Valley

23andMe CEO Anne Wojcicki speaks with Ed Ludlow at the Allen & Company Sun Valley Conference about healthcare trends, findings from a long covid study, and a telehealth acquisition.

4 months ago - Bloomberg Technology

Why 23andMe Stock Was Lagging the Market Today

The genetics company misses on both the top and bottom lines in its fourth quarter.

6 months ago - The Motley Fool

23andMe stock falls on widening loss

Shares of 23andMe Holding Co. ME, fell almost 7% in after-hours trading after the genetic-testing company saw its loss widen for the fiscal fourth quarter, and issued guidance that assumes the loss will...

6 months ago - Market Watch